Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reid W Merryman

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Hematology. American Society of Hematology. Education Program|December 7, 2019
Novel agents and immune invasion in Hodgkin lymphomaReid W Merryman, Ann LaCasce
Current Hematologic Malignancy Reports|February 4, 2017
Immune Checkpoint Blockade and Hematopoietic Stem Cell TransplantReid W Merryman, Philippe Armand
Cancer Journal (Sudbury, Mass.)|June 5, 2020
Immune and Cell Therapy in Non-Hodgkin LymphomaReid W Merryman, Roch Houot, Philippe Armand, et al.
Blood Advances|January 4, 2018
Checkpoint blockade in Hodgkin and non-Hodgkin lymphomaReid W Merryman, Philippe Armand, Kyle T Wright, et al.
Seminars in Nuclear Medicine|November 14, 2022
Interim FDG-PET/CT for Response Assessment of LymphomaMerissa N Zeman, Esma A Akin, Reid W Merryman, et al.
Blood Advances|March 3, 2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Allison C Rosenthal, Jennifer L Crombie, et al.
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Hematology. American Society of Hematology. Education Program|December 7, 2019
Novel agents and immune invasion in Hodgkin lymphomaReid W Merryman, Ann LaCasce
Current Hematologic Malignancy Reports|February 4, 2017
Immune Checkpoint Blockade and Hematopoietic Stem Cell TransplantReid W Merryman, Philippe Armand
Cancer Journal (Sudbury, Mass.)|June 5, 2020
Immune and Cell Therapy in Non-Hodgkin LymphomaReid W Merryman, Roch Houot, Philippe Armand, et al.
Blood Advances|January 4, 2018
Checkpoint blockade in Hodgkin and non-Hodgkin lymphomaReid W Merryman, Philippe Armand, Kyle T Wright, et al.
Seminars in Nuclear Medicine|November 14, 2022
Interim FDG-PET/CT for Response Assessment of LymphomaMerissa N Zeman, Esma A Akin, Reid W Merryman, et al.
Blood Advances|March 3, 2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Allison C Rosenthal, Jennifer L Crombie, et al.
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
Pageof 5